Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khalid Al-Rasadi

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|October 18, 2011
Benefits of lowering cholesterol in chronic kidney diseaseKhalid Al-Rasadi, Yajnavalka Banerjee
American Journal of Preventive Cardiology|June 15, 2026
Editorial commentary: From prevalence to practice - implementing familial hypercholesterolemia screening in high-risk clinics using an implementation science frameworkKhalid Al-Rasadi, Anurag Mehta
Journal of Clinical Lipidology|July 31, 2018
Use of cardiovascular risk scores in acute coronary syndrome patients with familial hypercholesterolemiaKhalid Al-Rasadi, Ibrahim Al-Zakwani
Oman Medical Journal|December 23, 2015
Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk OutcomeKhalid Al-Rasadi, Hilal Al-Sabti
Oman Medical Journal|December 9, 2017
New Treatments on the Horizon for Familial HypercholesterolemiaKhalid Al-Rasadi, Khalid Al-Waili
Expert Opinion on Pharmacotherapy|March 29, 2014
Treatment options for managing atherogenic dyslipidemia and fatty liver diseaseManfredi Rizzo, Giuseppe Montalto, Khalid Al-Rasadi
The New England Journal of Medicine|June 22, 2012
Effect of a monoclonal antibody to PCSK9 on LDL cholesterolYajnavalka Banerjee, Karna Shah, Khalid Al-Rasadi
Cardiovascular Drugs and Therapy|May 29, 2014
The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?Manfredi Rizzo, Dimitri P Mikhailidis, Khalid Al-Rasadi
Current Medicinal Chemistry|January 13, 2017
Lipoprotein (a) and Cardiovascular Risk: The Show Must go onNiki Katsiki, Khalid Al-Rasadi, Dimitri P Mikhailidis
Angiology|June 22, 2012
Will β-blockers live up to the maxim of Sir James Black, their creator?Khalid Al-Waili, Khalid Al-Rasadi, Yajnavalka Banerjee
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|October 18, 2011
Benefits of lowering cholesterol in chronic kidney diseaseKhalid Al-Rasadi, Yajnavalka Banerjee
American Journal of Preventive Cardiology|June 15, 2026
Editorial commentary: From prevalence to practice - implementing familial hypercholesterolemia screening in high-risk clinics using an implementation science frameworkKhalid Al-Rasadi, Anurag Mehta
Journal of Clinical Lipidology|July 31, 2018
Use of cardiovascular risk scores in acute coronary syndrome patients with familial hypercholesterolemiaKhalid Al-Rasadi, Ibrahim Al-Zakwani
Oman Medical Journal|December 23, 2015
Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk OutcomeKhalid Al-Rasadi, Hilal Al-Sabti
Oman Medical Journal|December 9, 2017
New Treatments on the Horizon for Familial HypercholesterolemiaKhalid Al-Rasadi, Khalid Al-Waili
Expert Opinion on Pharmacotherapy|March 29, 2014
Treatment options for managing atherogenic dyslipidemia and fatty liver diseaseManfredi Rizzo, Giuseppe Montalto, Khalid Al-Rasadi
The New England Journal of Medicine|June 22, 2012
Effect of a monoclonal antibody to PCSK9 on LDL cholesterolYajnavalka Banerjee, Karna Shah, Khalid Al-Rasadi
Cardiovascular Drugs and Therapy|May 29, 2014
The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?Manfredi Rizzo, Dimitri P Mikhailidis, Khalid Al-Rasadi
Current Medicinal Chemistry|January 13, 2017
Lipoprotein (a) and Cardiovascular Risk: The Show Must go onNiki Katsiki, Khalid Al-Rasadi, Dimitri P Mikhailidis
Angiology|June 22, 2012
Will β-blockers live up to the maxim of Sir James Black, their creator?Khalid Al-Waili, Khalid Al-Rasadi, Yajnavalka Banerjee
Pageof 15